Trial Profile
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2015
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Jun 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov.
- 10 Nov 2014 Planned number of patients changed from 0 to 1, according to the ClinicalTrials.gov record.
- 11 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.